Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate prices concessions, Bloomberg reported. The company told USA TODAY that it would ...

Global pharma major Lupin Limited announced on Friday the acquisition of anti-diabetes trademarks GIBTULIO, GIBTULIO MET and AJADUO from Boehringer Ingelheim International GmbH (Boehringer ...

More than 110,000 North Carolinians are projected to benefit from a $2,000 annual cap on out-of-pocket costs for covered prescription drugs for Medicare Part D participants.

After years of delays and debate, 2024 was the year when several health initiatives started to move forward. And advocates ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Medicare, in collaboration with Medicaid, has negotiated with pharmaceutical companies to reduce the prices of ten high-cost, ...

The cost-effectiveness body recommended ... events in high-risk patients. Jardiance was the trail blazer in this class, becoming the first diabetes drug to show a dual effect of reducing risk ...

A Connecticut federal judge has sided with the US Department of Health and Human Services (HHS) in Boehringer Ingelheim's challenge to Medicare’s drug price ... negotiate the prices of their ...

The share prices of Chinese concept stocks suffered a heavy blow, while pharmaceutical stocks soared. Is a wave of "privatization" returning to the market brewing? First generic! Hausen's ...

Gibtulio (empagliflozin), Gibtulio Met (empagliflozin + metformin) and Ajaduo (empagliflozin + linagliptin) belong to a novel class of oral anti-diabetic drug, sodium glucose cotransporter ... to ...